scholarly journals An overview on Coronaviruses family from past to Covid-19: introduce some inhibitors as antiviruses from Gillan’s plants

2020 ◽  
Vol 10 (3) ◽  
pp. 5575-5585 ◽  
Keyword(s):  
Physical Chemistry ◽  
Clinical Trials ◽  
Herbal Medicine ◽  
Virus Infection ◽  
Molecular Modelling ◽  
High Accuracy ◽  
Clinical Development ◽  
Binding Interaction ◽  
Active Constituents ◽  
Nmr Study

Among the herbal medicine that commonly used in relieving diseases we choose 4 species as the source for active constituents to be examined as its potential as anti SARS-CoV-2, namely Matrine, Cytarabine, Gemcitabine and Vidarabine from which are extracted from Gillan ‘s plants such as Trshvash, Chuchaq, Cote D’Couto and Khlvash in Iran. The mechanisms by which these agents exercise their antivirus action are calculated via analyzing of NMR and physical chemistry properties via docking. The drugs which are discussed in this article, some of them are in pre-clinical trials or clinical development and some are available in market such as Matrine, Cytarabine, Gemcitabine and Vidarabine. In this work, we have optimized and discussed about several active compounds which are extracted from famous plants through NMR study. These data in high-accuracy determine for anti-SARS-CoV-NSPs confirm our molecular modelling and also exhibited that Cytarabine, a compound found in Chuchaq, and Matrine from Trshvash, bind to those receptors with lower energies compared to the respected reference compounds. These finding indicated that both compounds possess better binding interaction and may inhibit the initial virus infection to the host cell

scholarly journals Therapeutic Index of Herbal Medicine in Pandemic COVID-19: A Review

2021 ◽  
Vol 11 (4) ◽  
pp. 4272-4279
Keyword(s):  
Clinical Trials ◽  
Plasma Concentration ◽  
Herbal Medicine ◽  
Viral Infections ◽  
Chemical Constituents ◽  
Therapeutic Index ◽  
The Novel ◽  
Therapeutic Level ◽  
Active Constituents ◽  
Different Types

The study of this review focus on effective herbal medicine against COVID-19. There have been many such plants on which a lot of research has been done earlier, and these have been very good for health as we know that the current situation of the whole world is very serious with the novel COVID-19 virus epidemic. Hence, people consume a lot of herbal medicine to increase their immunity, such as kadha (brewing), and it is also very effective against this viral infection. If we take brewing in the proper dose, research should be done from clinical trials. We have been taking many medicines since old times and have been doing research on them which is Antiviral and useful in different types of infection caused by bacteria, viruses, microbes, etc. The plant's diversity included their chemical constituents, showing the promise of their therapeutic level against the antiviral activity, without any toxicity with plasma concentration. Many plants show effectively against viral infections that are Flavonoids, Glycosides, polyphenols, alkaloids, etc.. Still, any clinical trials on humans do not prove their proper research on them, but the Chinese system of medicine claimed that Traditional Chinese medicine improves the COVID-19 patient. According to this review, we aim to collate data of plants the various large in the quantity of natural active constituents from individual medicinal plant species that may have potential therapeutic efficacy. The continuing development of novel antiviral drugs needs to isolate and synthesize more new active constituents.

New Anti-VEGF Drugs in Ophthalmology

2020 ◽  
Vol 21 (12) ◽  
pp. 1194-1200
Author(s):  
Claudio Campa
Keyword(s):  
Clinical Trials ◽  
Delivery System ◽  
Clinical Development ◽  
Advanced Stage ◽  
Phase 3 ◽  
Anti Vegf

: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. : Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.

Persian herbal medicine in functional dyspepsia: a systematic review article.

2020 ◽  
Vol 17 ◽  
Author(s):  
Maryam Azimi ◽  
Mohammad Javad Zahedi
Keyword(s):  
Clinical Trials ◽  
Herbal Medicine ◽  
Functional Dyspepsia ◽  
Nigella Sativa ◽  
Curcuma Longa ◽  
Crocus Sativus ◽  
Herbal Remedies ◽  
Asparagus Racemosus ◽  
Gastric Accommodation ◽  
Cynara Scolymus

Introduction: According to Rome IV, functional dyspepsia is diagnosed with presence of dyspepsia in the absence of organic or metabolic causes. FD caused by several factors such as impaired gastric accommodation and hypersensitivity to gastric distention. Several studies have reported effectiveness of herbal medicine on FD. This article, thus, reviews Persian herbal medicine in FD. Method: Electronic databases including Pubmed, Scopus, Cochrain, Embase, Web of science and Ovid were searched so as to find clinical articles related to dyspepsia and herbal medicine by July 2019. Our search strategies were traditional medicine, complementary and alternative medicine, herb, plant, and dyspepsia. We excluded all articles except Persian clinical trials. Results: We found 34 clinical trials with 15 herbs and 4 compound herbal remedies like Asparagus racemosus, Brassica oleracea, Cynara scolymus, Ocimum basilicum, Mentha longifolia, Mentha pulegium, Mentha piperata, Pimpinella anisum, Nigella sativa, Mastic gum, Curcuma longa, Pistatio atlantica, Glycyrrhiza glabra, Solanum tuberosum and Zingiber officinale and compound remedies of Rosa damascene & Crocus sativus, Trachyspermum copticom & Apium graveolence, Carum carvi & Mentha pipperata, Gingiber officinalis & Cynara scolymus are effective in functional dyspepsia. Conclusion: Many people use herbal and traditional remedies for treatment of disorders such as gastrointestinal disordersو , especially in Asian countries. Several studies reported the efficacy of herbal medicine in functional dyspepsia. Although their mechanisms are not fully understood, it seems they can modulate GI motility and improve symptoms of FD.

scholarly journals WEE1 Inhibitor: Clinical Development

2021 ◽  
Vol 23 (9) ◽  
Author(s):  
Anthony Kong ◽  
Hisham Mehanna
Keyword(s):  
Clinical Trials ◽  
Tp53 Mutation ◽  
Predictive Biomarker ◽  
Concurrent Chemotherapy ◽  
Clinical Development ◽  
Novel Agents ◽  
The Novel ◽  
Grade 3 ◽  
Chemotherapy Agents

Abstract Purpose of Review WEE1 inhibitor has been shown to potential chemotherapy or radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells although not exclusively. Here, we review the clinical development of WEE1 inhibitor in combination with chemotherapy or radiotherapy with concurrent chemotherapy as well as its combination with different novel agents. Recent Findings Although several clinical trials have shown that WEE1 inhibitor can be safely combined with different chemotherapy agents as well as radiotherapy with concurrent chemotherapy, its clinical development has been hampered by the higher rate of grade 3 toxicities when added to standard treatments. A few clinical trials had also been conducted to test WEE1 inhibitor using TP53 mutation as a predictive biomarker. However, TP53 mutation has not been shown to be the most reliable predictive biomarker and the benefit of adding WEE1 inhibitor to chemotherapy has been modest, even in TP53 biomarker-driven studies. Summary There are ongoing clinical trials testing WEE1 inhibitor with novel agents such as ATR and PAPR inhibitors as well as anti-PDL1 immunotherapy, which may better define the role of WEE1 inhibitor in the future if any of the novel treatment combination will show superior anti-tumor efficacy with a good safety profile compared to monotherapy and/or standard treatment.

scholarly journals The exosome journey: from biogenesis to uptake and intracellular signalling

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Sonam Gurung ◽  
Dany Perocheau ◽  
Loukia Touramanidou ◽  
Julien Baruteau
Keyword(s):  
Clinical Trials ◽  
Plasma Membrane ◽  
Scientific Community ◽  
Cell Types ◽  
Clinical Applications ◽  
Clinical Development ◽  
Intracellular Signalling ◽  
Clinical Settings ◽  
Health And Disease ◽  
Adequate Definition

AbstractThe use of exosomes in clinical settings is progressively becoming a reality, as clinical trials testing exosomes for diagnostic and therapeutic applications are generating remarkable interest from the scientific community and investors. Exosomes are small extracellular vesicles secreted by all cell types playing intercellular communication roles in health and disease by transferring cellular cargoes such as functional proteins, metabolites and nucleic acids to recipient cells. An in-depth understanding of exosome biology is therefore essential to ensure clinical development of exosome based investigational therapeutic products. Here we summarise the most up-to-date knowkedge about the complex biological journey of exosomes from biogenesis and secretion, transport and uptake to their intracellular signalling. We delineate the major pathways and molecular players that influence each step of exosome physiology, highlighting the routes of interest, which will be of benefit to exosome manipulation and engineering. We highlight the main controversies in the field of exosome research: their adequate definition, characterisation and biogenesis at plasma membrane. We also delineate the most common identified pitfalls affecting exosome research and development. Unravelling exosome physiology is key to their ultimate progression towards clinical applications.

Clinical Trials and Machine Learning: Regulatory Approach Review

2021 ◽  
Vol 16 ◽  
Author(s):  
Diego Alejandro Dri ◽  
Maurizio Massella ◽  
Donatella Gramaglia ◽  
Carlotta Marianecci ◽  
Sandra Petraglia
Keyword(s):  
Artificial Intelligence ◽  
Machine Learning ◽  
Clinical Trials ◽  
Patient Safety ◽  
Drug Discovery ◽  
Clinical Applications ◽  
Clinical Development ◽  
Regulatory Approach ◽  
National Competent Authorities ◽  
Review Current

: Machine Learning, a fast-growing technology, is an application of Artificial Intelligence that has significantly contributed to drug discovery and clinical development. In the last few years, the number of clinical applications based on Machine Learning has constantly been growing. Moreover, it is now also impacting National Competent Authorities during the assessment of most recently submitted Clinical Trials that are designed, managed, or generating data deriving from the use of Machine Learning or Artificial Intelligence technologies. We review current information available on the regulatory approach to Clinical Trials and Machine Learning. We also provide inputs for further reasoning and potential indications, including six actionable proposals for regulators to proactively drive the upcoming evolution of Clinical Trials within a strong regulatory framework, focusing on patient safety, health protection, and fostering immediate access to effective treatments.

scholarly journals PENGEMBANGAN SISTEM PAKAR PEMILIHAN JAMU DENGAN DIAGNOSA PENYAKIT PADA MANUSIA DENGAN METODE FORWARD CHAINING

2021 ◽  
Vol 9 (01) ◽  
pp. 11-18
Author(s):  
Teguh Pradana ◽  
Moch. Zul Ilmi ◽  
Teguh Arifianto
Keyword(s):  
Clinical Trials ◽  
Expert System ◽  
Herbal Medicine ◽  
Herbal Products ◽  
Forward Chaining ◽  
The Right

Herbal medicine is a medicine from natural ingredients whose properties have not been scientifically proven, in other words, it has not been subjected to clinical or clinical trials, but its properties are trusted by people based on experience. And at this time many herbal products are marketed in general, and not a few people are confused to choose the right herbal medicine according to their circumstances, so people have to consult or ask before choosing, and make the store experience a long queue on customers. Therefore an expert system is needed for herbal medicine so that people can choose the right herbal medicine according to their circumstances or conditions, and this system can reduce the queue at the herbal medicine shop customers. Expert system built in this study uses the forward chaining method. Case study for the system that is "Pasuruan herbal shop fan" which contained 70 types of herbal medicine, the results of tests conducted by this system are in accordance with the diagnosis.

scholarly journals Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design

US Neurology ◽  
2018 ◽  
Vol 14 (1) ◽  
pp. 47 ◽  
Author(s):  
Said R Beydoun ◽  
Jeffrey Rosenfeld
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Amyotrophic Lateral Sclerosis ◽  
Trial Design ◽  
Development Program ◽  
Clinical Trial Design ◽  
Clinical Development ◽  
Disease Heterogeneity ◽  
Clinical Development Program ◽  
Lateral Sclerosis

Edaravone significantly slows progression of amyotrophic lateral sclerosis (ALS), and is the first therapy to receive approval by the Food and Drug Administration (FDA) for the disease in 22 years. Approval of edaravone has marked a new chapter in pharmaceutical development since the key trial included a novel strategic clinical design involving cohort enrichment. In addition, approval was based on clinical trials that had a relatively small patient number and were performed outside of the US. Edaravone was developed through a series of clinical trials in Japan where it was determined that a well-defined subgroup of patients was required to reveal a treatment effect within the study period. Amyotrophic lateral sclerosis is associated with wide-ranging disease heterogeneity (both within the spectrum of ALS phenotypes as well as in the rate of progression). The patient cohort enrichment strategy aimed to address this heterogeneity and should now be considered as a viable, and perhaps preferred, trial design for future studies. Future research incorporating relevant biomarkers may help to better elucidate edaravone’s mechanism of action, pharmacodynamics, and subsequently ALS phenotypes that may preferentially benefit from treatment. In this review, we discuss the edaravone clinical development program, outline the strategic clinical trial design, and highlight important lessons for future trials.

Sign in / Sign up

Export Citation Format

Share Document